LEADER 02918 am 2200541 n 450 001 9910516003703321 005 20211013 010 $a2-84867-885-2 024 7 $a10.4000/books.pufc.39480 035 $a(CKB)4100000012293642 035 $a(FrMaCLE)OB-pufc-39480 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/86164 035 $a(PPN)260400262 035 $a(EXLCZ)994100000012293642 100 $a20220103j|||||||| ||| 0 101 0 $afre 135 $auu||||||m|||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aVotre Faust, la création en partage $eÉtude de la mise en scène d?Aliénor Dauchez : Votre Faust d?Henri Pousseur et Michel Butor /$fMarion Coste 210 $aBesançon $cPresses universitaires de Franche-Comté$d2021 215 $a1 online resource (310 p.) 225 1 $aAnnales littéraires 311 $a2-84867-649-3 330 $aVotre Faust est une « fantaisie variable genre opéra ». Cette dénomination, choisie par ses deux auteurs. Michel Butor et Henri Pousseur, témoigne de sa singularité. Lors de chaque représentation. le public est invité à modifier l?intrigue et la musique en votant et en criant. La collaboration étroite entre Michel Butor et Henri Pousseur, leur vision commune de l??uvre ouverte et engagée font de Votre Faust une pièce tant attrayante que déstabilisante. Marion Coste a été dramaturge pour la mise en scène française d?Aliénor Dauchez. Elle a fait le choix d?expliquer cette ?uvre complexe de l?intérieur, à partir des difficultés, des surprises et des joies rencontrées par les comédiens et les musiciens, sans pour autant renoncer à une approche technique du texte et de la partition. La première partie du livre permet d?explorer cette pièce, d?en fouiller l?immense intertexte littéraire et musical, et d?appréhender le fonctionnement participatif de l?écriture. L?accent est mis sur l?expérience sociale que constitue Votre Faust, sur scène et dans la salle. La seconde partie contient l?intégralité des entretiens réalisés avec une partie des musiciens, des comédiens, des techniciens et du public. 606 $aMusic 606 $aopéra 606 $amusique sérielle 606 $amythe de Faust 606 $anouveau roman 610 $aopéra 610 $amusique sérielle 610 $amythe de Faust 610 $anouveau roman 615 4$aMusic 615 4$aopéra 615 4$amusique sérielle 615 4$amythe de Faust 615 4$anouveau roman 700 $aCoste$b Marion$01319716 701 $aBosseur$b Jean-Yves$01319717 701 $aLe Diagon-Jacquin$b Laurence$01319718 801 0$bFR-FrMaCLE 906 $aBOOK 912 $a9910516003703321 996 $aVotre Faust, la création en partage$93034027 997 $aUNINA LEADER 05142nam 2200409 450 001 9910765705803321 005 20230323191246.0 010 $a3-03897-281-9 035 $a(CKB)5400000000000165 035 $a(NjHacI)995400000000000165 035 $a(EXLCZ)995400000000000165 100 $a20230323d2018 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aAML in the molecular age $efrom biology to clinical management /$fedited by Celalettin Ustun, Lucy A. Godley 210 1$aBasel, Switzerland :$cMDPI,$d[2018] 210 4$d©2018 215 $a1 online resource (196 pages) 225 0 $aJournal of clinical medicine 320 $aIncludes bibliographical references. 327 $aAbout the Special Issue Editors . vii -- Preface to "AML in the Molecular Age: From Biology to Clinical Management" ix -- Sophia Yohe Molecular Genetic Markers in Acute Myeloid Leukemia Reprinted from: J. Clin. Med. 2015, 4, 460-478, doi: 10.3390/jcm4030460 . 1 -- Gustavo M. Cervantes and Zuzan Cayci Intracranial CNS Manifestations of Myeloid Sarcoma in Patients with Acute Myeloid Leukemia: Review of the Literature and Three Case Reports from the Author's InstitutionReprinted from: J. Clin. Med. 2015, 4, 1102-1112, doi: 10.3390/jcm4051102 . 16 -- Elzbieta Gocek and George P. Studzinski The Potential of Vitamin D-Regulated Intracellular Signaling Pathways as Targets for Myeloid Leukemia Therapy Reprinted from: J. Clin. Med. 2015, 4, 504-534, doi: 10.3390/jcm4040504 . 25 -- Caroline Benedicte Nitter Engen, Line Wergeland, Jørn Skavland and Bjørn Tore Gjertsen Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions Reprinted from: J. Clin. Med. 2014, 3, 1466-1489, doi: 10.3390/jcm3041466 . 50 -- Marjan Cruijsen, Michael L ¨ubbert, Pierre Wijermans and Gerwin Huls Clinical Results of Hypomethylating Agents in AML Treatment Reprinted from: J. Clin. Med. 2015, 4, 1-17, doi: 10.3390/jcm4010001 . 69 -- Prithviraj Bose and Steven Grant Rational Combinations of Targeted Agents in AML Reprinted from: J. Clin. Med. 2015, 4, 634-664, doi: 10.3390/jcm4040634 . 83 -- Guldane Cengiz Seval and Muhit Ozcan Treatment of Acute Myeloid Leukemia in Adolescent and Young Adult Patients Reprinted from: J. Clin. Med. 2015, 4, 441-459, doi: 10.3390/jcm4030441 . 107 -- Jasmijn D. E. de Rooij, C. Michel Zwaan and Marry van den Heuvel-Eibrink Pediatric AML: From Biology to Clinical Management Reprinted from: J. Clin. Med. 2015, 4, 127-149, doi: 10.3390/jcm4010127 . 122 -- Gabriela Soriano Hobbs and Miguel-Angel Perales Effects of T-Cell Depletion on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes in AML Patients Reprinted from: J. Clin. Med. 2015, 4, 488-503, doi: 10.3390/jcm4030488 . 140 -- Nelli Bejanyan, Housam Haddad and Claudio Brunstein Alternative Donor Transplantation for Acute Myeloid Leukemia Reprinted from: J. Clin. Med. 2015, 4, 1240-1268, doi: 10.3390/jcm4061240 . 152 -- Nestor R. Ramos, Clifton C. Mo, Judith E. Karp and Christopher S. Hourigan Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia Reprinted from: J. Clin. Med. 2015, 4, 665-695, doi: 10.3390/jcm4040665 . 174. 330 $aIn this Special Issue, we aim to discuss important scientific and clinical ongoing activities in AML. Scientific subjects will include articles concerning the molecular abnormalities, epigenetic mechanisms of disease/therapy as well as the role of the immune system in AML. Very interesting and uncommon subjects will include discussions of extramedullary disease and evaluations of the central nervous system by various imaging techniques. Experts will describe the role of hypomethylating agents in the management of AML and currently emerging and promising investigational therapies. Specifics of treament of pediatric and younger patients with AML. Clinical success relies greatly on supportive therapy, and we will discuss supportive therapy, including infection prophylaxis. Allogeneic hematopoietic stem cell transplantation remains the most effective measure for curing aggressive AML, and a variety of topics will be considered: donor selection, age of recipient, which has been increasing seemingly without limit; therefore, recipient/donor assessments are more important than ever in the aging population. Alternative donor use (e.g., cord blood and haploidentical individuals) has been increasing dramatically; when and who should be considered, what is being investigated? With signi?cant changes occurring with respect to both donors and recipients, the pros and cons of using of anti-thymocyte globulin use in conditioning regimens will be also described. 517 $aAML in the Molecular Age 606 $aAcute myeloid leukemia 615 0$aAcute myeloid leukemia. 676 $a616.99/419 702 $aUstun$b Celalettin 702 $aGodley$b Lucy A. 801 0$bNjHacI 801 1$bNjHacl 906 $aBOOK 912 $a9910765705803321 996 $aAML in the molecular age$93395475 997 $aUNINA